The clarus Aspergillus Galactomannan EIA (AGM EIA) is an immunoenzymatic, sandwich microplate assay used for the qualitative detection of Aspergillus galactomannan in serum and bronchoalveolar lavage (BAL) samples from patients at-risk for invasive aspergillosis.
Serum |
EORTC | ||||||
Proven/Probable | No IA | Serum | Calculated | 95% CI | |||
IMMY clarus Asp. GM EIA | Pos. | 32 | 0 | Sensitivity | 84.2% | 69.6%-92.6% | |
Neg. | 6 | 216 | Specificity | 100.0% | 98.3%-100% | ||
BAL Fluid |
EORTC | ||||||
Proven/Probable | No IA | BAL Fluid |
Calculated | 95% CI | |||
IMMY clarus Asp. GM EIA | Pos. | 14 | 1 | Sensitivity | 87.5% | 64.0%-96.5% | |
Neg. | 2 | 19 | Specificity | 95.0% | 76.4%-99.1% |
AGM101 IVD IFU - English.pdf |
---|
AGM101 IVD IFU - French.pdf |
AGM101 IVD IFU - German.pdf |
AGM101 IVD IFU - Portuguese.pdf |
AGM101 IVD IFU - Spanish.pdf |
Aspergillus GM EIA | 96 tests | AGM101 |
---|